Accropeutics Secured $12 Million in Series B Plus Financing
Summary
Cash runway extended into the second half of 2026NEW YORK and SUZHOU, China, March 14, 2025 /PRNewswire/ -- Accropeutics Inc. (Accropeutics), a clinical-stage biotechnology company pioneering the development of novel therapeutics that target molecular mechanisms of regulated cell death for immune mediated diseases, today announced the closing of its $12 million Series B Plus financing. Xiaohu (Jason) Zhang, Co-founder and CEO of Accropeutics, stated: " With this round of financing, we are able to continue advancing our lead programs and solidify our position as an innovative, multi-program, clinical-stage biotech company. I am grateful to our existing and new investors, who share our vision that we can transform the treatment landscape for a wide range of I&I diseases with potentially best-in-class therapies. "Accropeutics Inc. is a clinical-stage biotechnology company pioneering the discovery, development and commercialization of novel therapeutics for immune mediated inflammatory disease, by targeting molecular mechanisms of regulated cell death. Accropeutics owns global rights for all of its assets, and boasts 23 issued patents in China, Japan, Korea, US and the EU.